BidaskClub Upgrades R1 RCM (NASDAQ:RCM) to “Sell”

R1 RCM (NASDAQ:RCM) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Tuesday, BidAskClub reports.

Several other research firms also recently commented on RCM. ValuEngine downgraded R1 RCM from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Robert W. Baird set a $14.00 price objective on R1 RCM and gave the stock a “buy” rating in a report on Thursday, September 12th. Finally, Zacks Investment Research upgraded R1 RCM from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Wednesday, October 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. R1 RCM has an average rating of “Buy” and an average target price of $13.40.

RCM opened at $10.15 on Tuesday. The stock has a 50-day moving average price of $10.06 and a 200-day moving average price of $11.37. The company has a debt-to-equity ratio of 106.30, a current ratio of 0.90 and a quick ratio of 0.90. The firm has a market cap of $1.13 billion, a PE ratio of -31.72 and a beta of 0.10. R1 RCM has a 1 year low of $7.10 and a 1 year high of $13.19.

R1 RCM (NASDAQ:RCM) last posted its quarterly earnings results on Tuesday, August 6th. The healthcare provider reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The company had revenue of $295.00 million during the quarter, compared to analysts’ expectations of $294.11 million. R1 RCM had a negative return on equity of 249.01% and a negative net margin of 2.22%. R1 RCM’s revenue for the quarter was up 41.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.07) EPS. As a group, sell-side analysts anticipate that R1 RCM will post 0.06 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of R1 RCM by 38.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,817 shares of the healthcare provider’s stock valued at $52,000 after purchasing an additional 1,625 shares during the period. Aperio Group LLC purchased a new position in R1 RCM in the 2nd quarter worth approximately $127,000. NumerixS Investment Technologies Inc lifted its holdings in R1 RCM by 73.3% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 10,400 shares of the healthcare provider’s stock worth $131,000 after purchasing an additional 4,400 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in R1 RCM in the 2nd quarter worth approximately $139,000. Finally, Bank of Montreal Can lifted its holdings in R1 RCM by 179.5% in the 2nd quarter. Bank of Montreal Can now owns 13,308 shares of the healthcare provider’s stock worth $168,000 after purchasing an additional 8,547 shares in the last quarter. Institutional investors own 70.87% of the company’s stock.

About R1 RCM

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.

See Also: Which market index is the best?

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.